These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 21838869)
41. Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR4 signaling pathway in vascular smooth muscle cells. Ji Y; Wang Z; Li Z; Liu J Cell Physiol Biochem; 2010; 25(6):631-40. PubMed ID: 20511708 [TBL] [Abstract][Full Text] [Related]
42. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis. Kottoor SJ; Arora RR J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850 [TBL] [Abstract][Full Text] [Related]
43. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864 [TBL] [Abstract][Full Text] [Related]
44. Atherosclerosis and interferon-γ: new insights and therapeutic targets. Voloshyna I; Littlefield MJ; Reiss AB Trends Cardiovasc Med; 2014 Jan; 24(1):45-51. PubMed ID: 23916809 [TBL] [Abstract][Full Text] [Related]
46. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML; JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434 [TBL] [Abstract][Full Text] [Related]
47. An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Crouse JR Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):287-304. PubMed ID: 18363544 [TBL] [Abstract][Full Text] [Related]
48. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ireland JH; Eggert CH; Arendt CJ; Williams AW Ann Intern Med; 2005 Jun; 142(11):949-50. PubMed ID: 15941707 [No Abstract] [Full Text] [Related]
49. Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage. Wu CH; Chen CC; Lai CY; Hung TH; Lin CC; Chao M; Chen SF J Neuroinflammation; 2016 Mar; 13(1):62. PubMed ID: 26968836 [TBL] [Abstract][Full Text] [Related]
50. Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. Liu B; Cao HM; Li GY; Liu M; Feng J; Li J; Wang Q J Int Med Res; 2011; 39(6):2314-22. PubMed ID: 22289549 [TBL] [Abstract][Full Text] [Related]
51. Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317. Peng D; Hiipakka RA; Reardon CA; Getz GS; Liao S Atherosclerosis; 2009 Mar; 203(1):59-66. PubMed ID: 18639878 [TBL] [Abstract][Full Text] [Related]
52. High-dose statins and atherosclerosis regression. von Birgelen C; Hartmann M JAMA; 2006 Oct; 296(15):1837; author reply 1837. PubMed ID: 17047210 [No Abstract] [Full Text] [Related]
53. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998 [TBL] [Abstract][Full Text] [Related]
54. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Schroeter MR; Humboldt T; Schäfer K; Konstantinides S Atherosclerosis; 2009 Jul; 205(1):63-73. PubMed ID: 19111832 [TBL] [Abstract][Full Text] [Related]
55. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412 [TBL] [Abstract][Full Text] [Related]
57. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796 [TBL] [Abstract][Full Text] [Related]
58. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445 [TBL] [Abstract][Full Text] [Related]
59. Lipingshu capsule improves atherosclerosis associated with lipid regulation and inflammation inhibition in apolipoprotein E-deficient mice. Xu J; Ma C; Chen M; Rong S; Gao H; Xia Z; Huang F Lipids Health Dis; 2018 Jul; 17(1):182. PubMed ID: 30064511 [TBL] [Abstract][Full Text] [Related]